Rockefeller scientists engineered an enhanced CD40 agonist antibody to fight cancer that has improved efficacy and is administered in a way that limits serious side effects. In recent clinical trial of 12 patients, six patients saw their tumors shrink, including two who experienced complete remission. The findings have sparked a number of other clinical trials involving a variety of cancers.
